CURRICULUM VITAE

ELEFTHERIOS GEORGAKOPOULOS

Address:

Skoufa str.2

10673 Athens, Greece

Phone:

Office: +30 210 3390340

Mob: +30 6944 630759

Email: derg@fgacenter.gr

www.fgacenter.gr

Personal Information:

Date of birth 13-08-1967

Place of birth Mannheim Germany

Eco. Status Married, father of 2 children

Interests Tennis, reading, history, moral philosophy, economics and business

Member Member of the Academy of Scientists of New York Union, the American Society of Advanced Sciences, Greek Students and Scientists of Mannheim (Association des Etats Generaux des Edudiatans de l' Europe), the Union of Scientists of the University of Heidelberg, the Hellenic Neurological Society, the Hellenic and European Biochemical Society, the Hellenic Society of Molecular Biology and Biochemistry

STUDIES - TITLES

1979-1982 High School Leaving Certificate, Second High School of Aspropyrgos

1982-1985 High School Leaving Certificate, A' Lyceum of Aspropyrgos

1987 to 1989 Study of Biology in Karl-Ruprecht University of Heidelberg.
Completion of the pre-graduate course and examination of the Pre-Diploma (Vordiplom).

1989 to 1992 Completion of Genetic and Molecular Biology seeds at Karl-Ruprecht University of Heidelberg. Final examinations in the following specialties:

Genetics	degree:	excellent
Biochemistry	degree:	excellent
Microbiology	degree:	excellent

Dissertation at the Institute of Molecular Genetics (Institut fuer Molekulare Genetik der Universitaet Heidelberg) of Karl-Ruprecht University of Heidelberg under the direction of the Director of the Institute of Molecular Genetics Prof. Dr. K.F. Bautz, and Prof. Dr. H. Matzura on:

" Stability of the cat-messenger RNA in *B. subtilis*".

1992 to 1995 Scholarship awarded by the Committee for Molecular and Cellular Neurobiology, Special Research Area 322 of the German Federal Research Society (Mollekulare und Zellulaere Neurobiologie, Sonderforschungsbereich 322, der Deutschen Forschungsgemeinschaft), and PhD thesis in II. Institute of Neurophysiology of the Medical School of Karl-Ruprecht University of Heidelberg (II. Physiologisches Institut der Universitaet Heidelberg) under the direction of Prof. Dr. Dr. Dr. h.c. M. Zimmermann and Prof. Dr. med. T. Herdegen on 'Expression and activation of constitutive and inducible transcription factors following transsynaptic seizures in the central nervous system of the adult rat'. Evaluation of research on diseases of the central nervous system (publications, announcements and presentations at international conferences and symposia), as

well as of general scientific knowledge with

Degree: Magna Cumlaude (Excellent)

LANGUAGES

Greek (native)

German fluently

English fluently

PROFESSIONAL AND SCIENTIFIC ACTIVITY

1991-1992 Thesis at the Institute of Molecular Genetics (Institut für Molekulare Genetik der Universität Heidelberg) of Karl-Ruprecht University of Heidelberg under the direction of the Director of the Institute of Molecular Genetics Prof. Dr. K.F. Bautz, and Prof. Dr. H. Matzura on:

"Stability of *cat* messenger RNA in the bacterium oB.subtilis", using techniques such as:

-DNA restriction, modification and transfection techniques

-sequencing analysis

-site directed point mutations and mutant selection

-nick transcription

-nucleic acid and protein transfer techniques

-primer extension analysis

-construction of recombinant plasmids (constructs)

-RNase protection assay

-S1 nuclease analysis

1992-1995 PhD thesis on "Expression and activation of constitutive and inducible transcription factors following transsynaptic seizures in the central nervous system of the adult rat", using various techniques such as:

-work with laboratory animals
-work with radioactive materials
- targeting and marking transcription nerve factors with radioactive materials
-development of cell cultures of idiopathic nerve cells
-monoclonal antibody production
-western blotting
-immune precipitation assay
-enhanced chemiluminescence
-in vitro transcription and translation
-south western blotting,
-EMSA
-gel shift
-super shift
-antsense oligonucketide techniques

3-95 - 8-95 Scientific Collaborator of Biological Chemistry Dept. of the Medical School of the University of Athens under the direction of Prof. Dr. K. Sekeris.

9-95 - 3-96 GlaxoWellcome S.A Clinical Trials Monitor for pharmaceutical drugs of central nervous system.

4-96 - 10-97 Fulfillment of my military obligations. Body: Sanitary.

11-97 - 09-01 Establishment, organization and management Department of Molecular Biology and Genetics, Athens Medical Center.
Development and integration of scientific research programmes (projects) in collaboration with scientific centers (see below).

1997 -09-01 Study of BRCA1 oncogene mutations and gene expression studies using methods:
-NIRCA (Non Radioactive RNA Cleavage Assay)
-hybridisation techniques

-PCR

-NT-PCR

-in situ hybridisation

-RT-PCR

-NT-RT-PCR

-quantitative PCR

-quantitative RT-PCR

- Restriction fragment length polymorphism (RFLP)

09-01 - 04-03 Foundation, organization and General Management of Biotechnology Department, Iatriki Techniki S.A., with major field inquiring and enterprising activities in the sector Molecular Diagnostics and Clinical Trials.

10-03 - 12-03 Senior Research Scientist, Forth Photonics Hellas SA, responsible for organizing and conducting clinical trials and investigations, handling regulatory issues related with the clinical trials, contacting and coordinating of basic research on the biophysics sector of Forth Photonics's technology, assessing competition and contributing to the development of Forth Photonics's Intellectual Property and Promoting the Forth Photonics's technology in both scientific and business communities.

01-04 -02-2006 President, CEO and Chief Scientific Officer of the NASDAQ-listed nanobiotechnology company Acrongenomics Inc., based in Nevada, United States of America. Responsible for the Research and Development in Nanotechnology and Biotechnology (see below), for the production of specific nanoparticles and their use in diagnostic procedures and applications, development of various cell cultures, implementation of quality control proccedures according to the quality standards of the Food and Drug Administration (FDA, USA), production of prototypes and the conduct of clinical studies of various phases in accordance with the Good

Clinical Practice Protocol and the International Harmonized Act (Good Clinical Practice GCP and Harmonization Act), funding of the company's research programs through the American Private Placement (PPM), the presentation of the company's research and financial results both to U.S. State Institutions and to institutional and other investors and companies in Asia, Europe and USA. The technology developed at the level of Nanotechnology and its applications in Biotechnology has been registered with a series of national and international Patents (see below) as well as worldwide as a trademark with the acronym Nano-JETA™ technology. Some of the methods developed were:

- Downscale nanoparticle production.
- Upscale nanoparticle production.
- Super magnetic nanoparticle production.
- Spherical nanoparticle production.
- Layer per layer nanoparticle production.
- Determination of nanoparticle quality and quantity.
- Determination of produced nanoparticle of physical, chemical and biological properties.
- Implementation of different origin nanoparticles in PCR application.
- Implementation of different origin nanoparticles in Reverse Transcription PCR application.
- Implementation of different origin nanoparticles in Real Time PCR application.
- Implementation of different origin nanoparticles in ELISA.
- Cell culture techniques
- Quality Control Assessments for Research and Development as well as for prototype production unit for use in clinical studies.

02/2006-10/2006 Genetic Counselling in “Levkos Stavros” Hospital.

02/-2006-02/2008 CSO and member of the Board of Directors of Biocenter S.A., for biomolecular applications in patients with various pathophysiological and pathological conditions neurological diseases such as Friedreich's ataxia, lateral sclerosis, sensory and motor type polyneuropathy, injuries, well-being etc.

03/2008-10/2008 Quality System Director, Stem-Health S.A., Medical Technology Greek Stem Cell Bank S.A., Genetic Technology, responsible for creating, organization, implementation and operation of a total Quality System according to NetCord-FACT, FDA and European Union guidelines.

11/2008-05-2010 Detox Center S.A., Athens Greece, appointed as Geneticist and Molecular Biology expert responsible for metabolomic applications in biological samples (blood, urine and plasma) and elaboration in daily practice in various pathophysiological and pathological conditions as well as in well-being. Elaboration of supplementative medicine in various pathophysiological and pathological conditions as well as in well-being with excellency.

6/2010-today Foundation and Chief Executive Officer and Chief Scientific Officer of Functional Genomic Applied Center, Athens Greece, in the field of Precision Medicine performing Biochemical Genetic – Metabolomic analysis in biological samples (blood, urine and plasma, up to 11.800 samples examined) and elaboration in daily practice in various pathophysiological and pathological conditions as well as in well-being and Single Nucleotide Polymorphism detection analysis (up to 500 samples eamined) and counselling in various diseases such as preventive and well-being, metabolic syndrome, obesity, psoriasis and psoriatic arthritis, rheumatoid arthritis, multiple sclerosis, irritable bowel syndrome and inflammatory bowel syndrome (Crohn’s disease and ulcerative colitis, male and female infertility etc. Elaboration of supplementative medicine in various pathophysiological and pathological conditions as well as in well-being with excellent results.

ATTENDANCE OF POSTGRADUATE SEMINARS

9-99 Postgraduate seminar in Dublin, Ireland, under the auspices of the symposium entitled:
«MR Screening in Women at High Genetic Risk of Breast Cancer. Current and Planned Studies, International Collaboration and Combined Analysis».

10-99 Postgraduate seminar in Athens, Greece, under the auspices of the European School of Oncology on:
«Training Course on Drug Targeting».

CONDUCTING SEMINARS

10-92 – 2–93 Head of the Molecular Genetics Laboratories of the undergraduate course of studies in Biology at the Institute of Molecular Genetics of the University of Heidelberg in the field of "Gene shock and gene analysis of Gram-positive plasmids".

10-94 – 2-95 Series of educational seminars at the University of Heidelberg, entitled:
"Molecular genesis program of the nerve cell after transsynaptic stimulation".
"Effect of the phenomenon of epilepsy on the molecular mechanisms of the nerve cell of the central nervous system".

3 - 95 – 6 – 95 Series of circular postgraduate seminars in students in Biological Chemistry of the Medical School of the University of Athens, on:
"Molecular genetics and transcriptional activities of prokaryotic and eukaryotic cells: Similarities and differences".
"Physiology of the central nervous system".
"Effect of epilepsy phenomenon on the genetic cellular program in the central nervous system."

9-1999.1.1 Organization and realization of a cycle of postgraduate courses at the Oncology Clinic of Athens Medical Center on:
"The organization of genes in eukaryotic organisms"
"The process of DNA replication".
"Transcription in prokaryotes and eukaryotic organisms"
"Protein synthesis and factors involved in this process"
"Mutations, their importance and mechanisms of genetic repair"
"Oncogenes and tumor suppressor genes: The role of gatekeepers"
"Molecular Biology in clinical practice: Methods and practices of

particular importance"

10-2000 Organization and realization of a series of postgraduate seminars at the First and B' Surgical Clinic of Konstantopoulio Hospital "Agia Olga" with the following topics:

"Gene organization in prokaryotic and eukaryotic organisms: Similarities and differences"

"The replication of DNA".

"Transcription in prokaryotes and eukaryotic organisms"

"Protein synthesis and factors involved in this process"

"Mutations, their importance and mechanisms of genetic repair"

"Oncogenes and tumour suppressor genes: The role of gatekeepers"

"Molecular Biology in Research and Clinical Practice: Methods and Practices of Particular Clinical Importance"

09-01 to 04-2003 Supervision of the execution of PhD Dissertations performed at the Department of Biotechnology of Iatriki Techniki S.A.:

1. PhD thesis of Dr. Konstantinos Vlahtsis: "The role of oncoproteins, associated with apoptosis and angiogenesis, in the prognosis of surgically excluded laryngeal cancer".

2. PhD thesis of Dr. Karanikiotis Charisios: "The influence of immunogenetic factors on the course and outcome of patients with nasopharyngeal cancer".

3. PhD thesis of Dr. Eleni Ress: "Prognostic and predictive significance of detecting microsatellite DNA (MSI) instability by PCR as well as expression of COX2 and TOPO-I, in patients with resectable colorectal cancer stage B2 and C who underwent adjuvant chemotherapy".

4. PhD thesis of Dr. Korakianitis Georgiou, Resident Urology Clinic of the General Hospital of Athens "Evangelismos": "In vitro cytotoxicity of bisphosphonate Zoledronate (Zometa) in combination with corticosteroids and antiandrogens in prostate cancer cell lines and study of activation of apoptosis mechanism and angiogenesis inhibition mechanism".

5. PhD thesis of pathologists Tzaida Olympia and Papaspyrou Eirini: "The prognostic role of oncoproteins HER1, HER2 in the clinical course and response to treatment of patients with high-risk breast carcinoma".

6. PhD thesis of the physician Pathologist – Oncologist Stefanos Lambropoulos: "The prognostic role of oncoproteins of the HER family in the clinical course and response to the treatment of patients with breast carcinoma".

7. PhD thesis of Moutzouris Vassiliou, Resident at the Urology Clinic of P.G.N.A., "Evangelismos: "In vitro cytotoxicity of monoclonal antibody 17-1A in prostate cancer cell lines and study of activation of the mechanism of apoptosis".

8. PhD thesis of biologist Stavroula Georgakopoulou: "The prognostic significance of the expression of oncoproteins, HER 1, HER2, TS, proteins involved in the processes of apoptosis (bcl_2) and angiogenesis, (v EGF) in patients with resectable colorectal cancer stage B2 and C who underwent adjuvant chemotherapy".

PROJECTS

Since 2008 up today, I'm working in the field of Precision Medicine performing Biochemical Genetic – Metabolomic analysis in biological samples (blood, urine and plasma, up to 11.800 samples examined) and elaboration in daily practice in various pathophysiological and pathological conditions as well as in well-being and Single Nucleotide Polymorphism detection analysis (up to 500 samples eamined) and counselling in various diseases such as preventive and well-being, metabolic syndrome, obesity, psoriasis and psoriatic arthritis, rheumatoid arthritis, multiple sclerosis, irritable bowel syndrome and inflammatory bowel syndrome (Crohn's disease and ulcerative colitis, male and female infertility etc. Elaboration of supplementative medicine in various pathophysiological and pathological conditions as well as in well-being with excellent results.

My activities in Acrongenomics Inc. were in multiple aspect of the company. Acrongenomics Inc., a research and development company, was active in the field of Nanobiotechnology. As a listed company on the NASDAQ stock exchange, it used the procedures as provided by the laws and regulations of the U.S. Securities and Exchange Commission in order to raise the necessary funds to carry out the company's research and development program. During this period, funds totalling €10,000,000 were raised to finance the company's needs.

The company created a vertically integrated quality control system for all internal processes and operations in all its departments (R&D with subdepartments: Elementary Particle in Physics, in vitro Cell Cultures, Molecular Applications, ELISA, animal management, prototyping, clinical research, marketing, share management, financial services, etc.) as provided by the FDA regulations (for the scientific part) from which it was regularly audited and by the U.S. Securities and Exchange Commission (for other departments).

The company's research program aimed to develop nanoparticles and identify their properties for use in clinical applications. The procedures are described in detail in accordance with the patent regulations described below. The immediate priorities were to investigate the use of nanoparticles in various applications such as drug delivery, cell

efficacy as cytostatics with in vitro and in vivo experiments, as well as their use in diagnostic applications such as reverse transcription, polymerase chain reaction (PCR), , Real Time PCR and ELISA. The applications are described as provided by international patent organizations in the patents given below. At the same time, relevant studies were conducted using electron microscope, Z-Dynamic, FAM, etc. for the identification and standardization of nanoparticle production. Also, for a series of applications under development of the company, comparative studies were conducted using other nanoparticles either by commercial companies around the world (production areas Europe Asia and USA) or by scientific research institutes in Europe and US.

The results led to the registration of a brand name for the global market with the acronym Nano-JETATM technology. The technology also included the development of a special mathematical model and its operation in real conditions on the screen for Real Time PCR machines, which is described in an appendix since there is no provision for the relevant patenting of mathematical models.

At the same time, pilot production of prototypes of Real Time PCR diagnostic applications (kit's for DNA and RNA quantitation) for a number of pathological factors was implemented and idented to conduct relevant clinical studies. The standardization and labeling of the original products took place in accordance with the rules and regulations provided by the European Union (CE-mark), Good Manufacturing Practice (GMP) and the FDA.

For the first time worldwide, results were produced using nanoparticles other than gold nanoparticles as first described by Dr. Mirtski and later by other colleagues. Nanoparticles based on another kind of structure (according to the production process), giving amazing results.

Following the establishment and organization of the Molecular Biology Unit at Athens Medical Center, I developed particular activity in a series of research programs in collaboration with scientific and pharmaceutical companies:

1. Development and implementation of a research programme entitled:
«BRCA1 Mutations in Hereditary Breast Cancer in Greek Population».
The project was funded by Athens Medical Center.

2. Development and submitted a research program for the control and operation of a pharmaceutical preparation of GlaxoWellcome entitled:
"Administration of Lamivudine to patients carrying chronic hepatitis B".
The program consists of two phases, was executed at the Department of Molecular Biology, Athens Medical Center and was funded entirely by the pharmaceutical company.

3. Development and submitted a research program for a pharmaceutical formulation of the company Hoffman - La Roche to the scientific company HECOG entitled:
"Comparison and evaluation by immunohistochemistry and quantitative reverse transcription PCR (RT-PCR) of *p53* and *c-erbB-2 gene expression*".
The project was funded by the scientific society HeCoG.

4. Development and submitted a research program for the determination of a possible molecular marker through the detection of mRNA for the presence of metastatic cancer cells in peripheral blood and pathological tissues entitled:
«Detection of the mRNA of GA 733-2: a potent marker for identification of metastatic cancer cells in patients with colorectal cancer».
This research project was funded by the pharmaceutical company GlaxoWellcome.

5. Co-development and submission to the National Organization for Medicines and execution of a research protocol for the study of the activity of the monoclonal antibody Endrecolomab in hormone-resistant prostate cancer.

This research project was funded by the pharmaceutical company GlaxoWellcome.

The Department of Biotechnology of Iatriki Techniki S.A. was active in the field of Molecular Diagnostics. Since its establishment in full operating scale, research programs have been funded by both the Department of Biotechnology and other partners as follows:

1) GVG 2000 program

"Evaluation of the use of set of sense and antisense controls for the detection of micrometastatic disease"

Sponsor Company: P.N. Gerolymatos S.A. , Greece

Conducted by: Department of Biotechnology, Iatriki Techniki S.A.

2) ITBD Program 01/02

"Evaluation of lamivudine administration in patients with chronic hepatitis B"

Sponsor Company: GlaxoSmithKline S.A., Greece

Conducted by: Department of Biotechnology, Iatriki Techniki S.A.

3) M23153 Programme

"Evaluation of ribavirin and interferon in patients with hepatitis C"

Sponsor Company: Hoffman La Roche Hellas S.A., Greece

Conducted by: Department of Biotechnology, Iatriki Techniki S.A.

4) ITBD Program 03/02

'Pharmacovigilance assessment'

Sponsor Company: GlaxoSmithKline S.A., Greece

Conducted by: Department of Biotechnology, Iatriki Techniki S.A.

5) ITBT Project 04/02

"Detection of tubulin mutations in patients resistant to chemotherapy use"

Sponsor: HECOG

Conducted by: Department of Biotechnology, Iatriki Techniki S.A.

6) ITBD Program 05/02

« Molecular detection of micrometastasis and circulating cancer cells in lymph node-positive patients with breast cancer"

Sponsor Company: Department of Biotechnology, Iatriki Techniki S.A.

Conducted by: Department of Biotechnology, Iatriki Techniki S.A.

7) ITBD Program 07/02

"The role of oncoproteins associated with apoptosis and angiogenesis in the prognosis of surgically resectable laryngeal cancer".

Sponsor Company: Department of Biotechnology, Iatriki Techniki S.A.

Conducted by: Department of Biotechnology, Iatriki Techniki S.A.

8) ITBD Program 08/02

"The influence of immunogenetic factors on the course and outcome of patients with nasopharyngeal cancer"

Sponsor Company: Jansen Cilag S.A., Greece

Conducted by: Department of Biotechnology, Iatriki Techniki S.A.

9) ITBD Program 09/02

"The prognostic role of TP and TS in patients with high-risk resectable rectal and colorectal cancer with FU/LEUCOVORIN chemotherapy".

Sponsor Company: Department of Biotechnology, Iatriki Techniki S.A.

Conducted by: Department of Biotechnology, Iatriki Techniki S.A.

10) ITBD Program 10/02

"The prognostic importance of VEGF and BCL2 proteins in the clinical course and response to CMT with 5 FU/LEUCOVORIN patients with resectable colorectal cancer

and possible association between them".

Sponsor Company: Department of Biotechnology, Iatriki Techniki S.A.

Conducted by: Department of Biotechnology, Iatriki Techniki S.A.

11) ITBD Program 11/02

"Detection of HER family oncoproteins in high-risk breast cancer (UN 10/97)".

Sponsor Company: Hoffman La Roche S.A., Greece

Conducted by: Department of Biotechnology, Iatriki Techniki S.A.

12) ITBD Program 12/02

"Detection of HER group oncoproteins in peripheral blood of patients with metastatic breast cancer (UN 11B/02)".

Sponsor Company: Astra Zeneca S.A., Greece

Conducted by: Department of Biotechnology, Iatriki Techniki S.A.

13) ITBD Programme 13/02

"Detection of expression of CK 19, Ep-CAM antigen and micrometastatic cancer cells in peripheral blood of patients with resectable breast cancer with positive lymph nodes receive chemotherapy E-T-CMF vs ET-CM)."

Sponsor Company: Department of Biotechnology, Iatriki Techniki S.A.

Conducted by: Department of Biotechnology, Iatriki Techniki S.A.

14) ITBD14/02 Project

"In vitro cytotoxicity of zoledronate bisphosphonate (Zometa) in combination with corticosteroids and antiandrogens in prostate cancer cell lines and study of activation of apoptosis mechanism and angiogenesis inhibition mechanism".

Sponsor Company: Novartis Greece S.A.

Conducted by: Department of Biotechnology, Iatriki Techniki S.A.

15) ITBD Program 15/02

"In vitro cytotoxicity of monoclonal antibody 17-1A in prostate cancer lines".

Sponsor Company: GlaxoSmithKline S.A & Jansen Cilag S.A. Greece

Conducted by: Department of Biotechnology, Iatriki Techniki S.A.

16) ITBD Program 16/02

"Prognostic and predictive significance of MSI in patients with resectable stage B2 and C colorectal cancer undergoing adjuvant chemotherapy."

Sponsor: HECOG

Conducted by: Department of Biotechnology, Iatriki Techniki S.A.

17) ITBD Programme 17/02

"Study of apoptosis and angiogenesis in patients with resectable non-small cell lung cancer undergoing adjuvant chemotherapy".

Sponsor: HECOG

Conducted by: Department of Biotechnology, Iatriki Techniki S.A.

18) ITBD Program 19/02

"Molecular detection of Ep-CAM antigen tissues, bone marrow and peripheral blood of patients with metastatic colorectal cancer".

Sponsor Company: Department of Biotechnology, Iatriki Techniki S.A.

Conducted by: Department of Biotechnology, Iatriki Techniki S.A.

19) ITBD Program 23/02

«A highly efficient and rapid RNA isolation procedure from formalin fixed paraffin embedded tissue for reverse transcription PCR(RT-PCR)».

Sponsor Company: Department of Biotechnology, Iatriki Techniki S.A.

Conducted by: Department of Biotechnology, Iatriki Techniki S.A.

During my employment at GlaxoWellcome, I was assigned the development of a research program for the control and operation of a proprietary medicinal product of the company entitled: "Research program on Lamictal for the improvement of the drug: mechanism of action, interactions and neuropeptides".

PATENTS

1. Patent No. 1003455 and title:
"New method of detecting 17-1A in peripheral blood and tissues and identifying metastatic cancer cells in patients with various types of cancer".

2. Patent to the Industrial Property Organisation under Number 1004303 entitled:
"New method of detecting 17-1A in peripheral blood and tissues and identifying metastatic cancer cells in patients with various types of cancer".

3. Patent No. 1003896 titled: "New method for detection and identification of point mutations of hepatitis B virus (HBV) strains in patients' blood serum".

4. Patent No. 1003878 titled: "New method of isolation of total ribonucleic acids (total RNA) from paraffin tissues".

5. Patent at the Industrial Property Organization with Application Number 990100391 entitled: "New method for detection of Ep-Cam cancer membrane antigen and determination of circulating micrometastatic cancer cells in peripheral blood of patients (and tissues) with cancer of epithelial origin".

6. NCBI approved patent for the membrane cancer antigen sequence Ep-CAM.

7. EPO approved patent for the molecular detection of membrane cancer antigen Ep-CAM.

8. Patent modification with Number 1004765 on Patent with Number 1004303 titled: «Detection of cancer membrane antigen Ep-Cam and determination of circulating micro-metastatic cancer cells in peripheral blood of patients (and in tissues) with cancer of epithelial origin».

9. Patent with Number 1004959, titled: "Prototype RT and PCR protocols with the use of Neowater for the detection epithelial cell adhesion molecule EpCAM and detection of circulating micro-metastatic cancer cells in peripheral blood (and tissue) of patients with cancer of epithelial origin".

10. Patent with Number 1004961, titled: "Prototype RT and PCR protocols with reduced quantities of reagents without MgCl2 and with the use of Neowater for the detection epithelial cell adhesion molecule EpCAM and detection of circulating micro-metastatic cancer cells in peripheral blood (and tissue) of patients with cancer of epithelial origin".

11. Patent with Number 1004964, titled: "Prototype RT and PCR protocols, with minimal concentration of reagents, without magnesium chloride using Neowater and detection of cancer membrane antigen Ep-Cam and identification of circulating micrometastatic cancer cells in peripheral blood (and tissues) in patients with cancer of epithelial origin".

12. Patent with Number 1004965, titled: "Prototype RT and PCR protocols using Neowater without use of the reverse primer and magnesium chloride and detection of cancer membrane antigen Ep-Cam and identification of circulating micrometastatic cancer cells in peripheral blood (and tissues) in patients with cancer of epithelial origin".

13. European Patent with Number EP1612278, titled: "Method for the detection and identification of epithelial micro-metastatic cancer cells".

14. Patent with Application Number 20060014174 Submitted to US Patent Office, titled: "Method for the detection and identification of epithelial micro-metastatic cancer cells".

15. Patent with Number CA 2502756 (Canadian Patent Office), titled: "Method for the detection and identification of epithelial micro-metastatic cancer cells".

16. Patent with Number 20050100370 Submitted to Greek Industrial Organization Office (pending), titled: **"**Detection and quantification of nucleic acids (DNA/RNA) in peripheral blood, tissues and body fluids".

17. Patent with Number 20050100 Submitted to Greek Industrial Organization Office (pending), titled: "Detection and quantification of nucleic acids (DNA/RNA) in peripheral blood, tissues and body fluids".

AWARDS

1) 2000: 9th Hellenic Congress of Clinical Oncology, April 2000.
2) 2000: European Association of Medical Oncology, 25th ESMO Congress, 2000.

3) 2001: 10th Hellenic Congress of Clinical Oncology, April 2001.

4) 2002: Award from the Minister of Development and the Organization of Industrial Property for my invention with number 1003455 and title: « New method of detection of 17-1A in peripheral blood and in tissues and determination of micrometastatic cancer cells in patients with various types of cancer ».
5) 2002: HPV and EBV infection and their relation to apoptosis and angiogenesis related proteins in operable laryngeal carcinomas, ESMO, October 2002.
6) 2002: For significant Accomplishments and Achievements, Greek Republic.

7) 2003: The infection with EBV and HPV and their relation with the expression of *bcl-2*, *wt-p53*, *vEGF* and *HER1* in patients with operable laryngeal cancer, 12th North Greek Medical Congress, May 2003.

8) 2003: Marquis Who's WHO Organization, Who is Who In the World, 21rst Edition, 2004.

9) 2004: 2000 Outstanding Intellectuals of the 21st Century, International Biographical Centre, Cambridge, England.

10) 2004: Man of the Year, International Biographical Centre, Cambridge, England.

11) 2004: Great Minds of the 21st Century, American Biographical Institute, U.S.A.

12) 2004: International Peace Prize, United Nations Cultural Convention, U.S.A.

13) 2004: Marquis Who's WHO Organization, Who is Who In the World, 22rst Edition, 2005.

14) 2004: 21st Century Award for Achievement, Illuminated Diploma Of Honour, International Biographical Centre, Cambridge, England

15) 2005: Marquis Who's WHO Organization, Who is Who In the World, 23rst Edition.

16) 2005: American Medal of Honor, American Biographical Institute, U.S.A.

17) 2005: Man of the Year, Registered in the Institute Library and Archives in the United States of America, American Biographical Institute, U.S.A.

ACTIVE PARTICIPATION IN CONFERENCES

1. European Society of Neuroscience, 1994
2. Society for Neuroscience, 1995
3. 23rd Goetingen Neurobiology Conference.
4. MR Screening in Women at High Genetic Risk of Breast Cancer. Current and Planned Studies, International Collaboration and Combined Analysis
5. 22nd International Breast Cancer Research Congress of the IABCR
6. 9th Panhellenic Congress of Clinical Oncology, April 2000. Our work was awarded the first prize*.
7. European School of Oncology, Athens 1999.
8. European School of Oncology, Kos 2000.
9. HeCG meetings every four months during 2000*.
10. European Association of Cancer Research, XVI EACR Congress, 2000.
11. European School of Oncology, Thessaloniki 2000.
12. HeCOG Meeting, October 2000*.
13. European Association of Medical Oncology, 25th ESMO Congress, 2000.
14. Association of Biomedical Technology of Crete, November, 2000*.
15. 10th Panhellenic Congress of Clinical Oncology, April 2001*.
16. Series of lectures invited by the German Federal Minister of Health, Duesseldorf, June 2001*.
17. Biotechnology Meeting, Mykonos, July 2001*.
18. HeCG meetings every four months during 2001*.
19. Association of Biomedical Technology of Crete, November, 2001*.
20. HPV and EBV infection and their relation to apoptosis and angiogenesis related proteins in operable laryngeal carcinomas, ESMO, October 2002.
21. Detection of HER 1, HER 2, HER 3 and HER 4 in patients receiving Taxol+Carboplatin+Iressa with advanced breast cancer, HECOG, June 2002.
22. Infection with EBV and HPV viruses and their relationship to proteins involved in apoptosis and angiogenesis in surgically resectable laryngeal cancer, HECOG, June 2002*.

23. The prognostic role of proteins involved in apoptosis and angiogenesis in patients with high-risk resectable rectal and colorectal cancer following chemotherapy treatment with FU/LEUCOVORIN according to HECOG protocols: He 6c/91, He 6d/91 He 6d/98, He 6d/99, He 6c/98, He 6c/99, He 6e/99, HECOG, June 2002.

24. The prognostic role of TP and TS proteins in patients with high-risk resectable rectal and colorectal cancer following chemotherapy treatment with FU/LEUCOVORIN according to HECOG protocols: He 6c/91, He 6d/91, He 6d/98, , He 6d/99, He 6c/98, He 6c/99, He 6e/99, HECOG, June 2002.

25. From idea to OBI and PCT process, Crete May 2002*.

26. Targeting HER-2 and EGFR, HAPSc, August 2002*.

27. The contribution of molecular techniques to the determination of prognosis, HAPSc, September 2002*.

28. Detection of Ep-Cam antigen in patients with metastatic breast cancer, HECOG, October 02.*

29. The contribution of translational research to the establishment of new prognostic and predictive factors in breast cancer, HECOG, October 02*.

30. Infection with EBV and HPV viruses and their relationship to proteins involved in apoptosis and angiogenesis in surgically resectable laryngeal cancer, 10th Postgraduate Seminar of Clinical Oncology, Crete, November 2002*.

31. Detection of mRNA CK-19 and Ep-Cam antigen and micrometastatic cancer cells in patients with resectable node-positive breast cancer receiving E-T-CMF vs ET-CMF chemotherapy, 10th Postgraduate Seminar of Clinical Oncology, Crete, November 2002*.

32. Molecular diagnostics and cancer. New approach to detecting residual disease. A new PCR product detection system, Panhellenic Congress of Clinical Chemistry, Athens, November 2002*.

33. Use of metabolomic techniques for the detection of disturbances in digestion, absorption and to identify how affect the cellular procedures, educative seminar, October 2010, by Lamberts. S.A., Greece*.

34. Seminars in Nutritionists for interpretation of metabolomics results, 2011 &

2012*.

35. What is precision medicine, techniques used for results interpretation and how supplements can be used in daily praxis, Symmetria S.A., 2022*

36. Antiaging and Skin, Sothys S.A. Greece, 2024*

37. The Principle of Whole, Hippocratic Week, Kos 2024*.

*Invited Speaker

Presentations in Conference

Georgakopoulos E., Gass P., Schmid W., Kiessling M., Bravo R., Zimmerman M and Herdegen T (1994)*: «Phosphorylation of CREB and SRF, and expression of CREM, Jun, Fos and Krox transcription factors in the rat brain following seizure activity». European Journal of Neuroscience, Suppl. **7**: 45.08.

Herdegen T., Gass P., Brecht T., Schmid W., **Georgakopoulos E.**, Hajek I., Bravo R. and Zimmermann M. (1994): «Transection of central and peripheral nerve fibers selectively effects the expression and phosphorylation of CREB, CREM and SRF proteins in axotomised neurons». European Journal of Neuroscience, Suppl. **7**: 119.05.

Herdegen T., **Georgakopoulos E.**, Brecht T., Schmid W., Bravo R and Gess P. (1994)*: «Expression and activation of CREB, CREM ATF,SRF and Jun, Fos transcription factors: key events for selective control of gene induction in the nervous system». Abstracts of the Society for Neuroscience, **20**: 270.7.

Georgakopoulos E., Blume A., Gas P., Zimmermann M and Herdegen T. (1995): «Phosphorylation of CREB and SRF, expression of Jun, Fos and Krox proteins and activation of the *c-jun* promotor following generalised seizures». Proccedings of the 23rd Goetingen Neurobiology Conference.

Georgakopoulos E., Kapridaki E., Papageorgiou G., Georgakopoulou S and Garas I. (1998)*****: «BRCA1 Mutations in Hereditary Breast Cancer in Greek Population». Proceedings of MR Screening in Women at High Genetic Risk of Breast Cancer. Current and Planned Studies, International Collaboration and Combined Analysis

E. Georgakopoulos*, C. Christodoulou, G. Klouvas, S. Georgakopoulou, G. Vogiatzis and D. Skarlos: "Detection of mRNA antigen 17-1A in peripheral blood of patients with hormone-resistant prostate cancer", 9th Panhellenic Congress of Clinical Oncology, April 2000. The paper was awarded the first prize.

E. Georgakopoulos*, C. Christodoulou, G. Klouvas, S. Georgakopoulou, G.Bogiatzis and D.Skarlos: «Detection of the 17-1A Antigen mRNA in Circulating Blood and the Efficacy of the Monoclonal Antibody Enderocolomab in Patients with Hormone Prostate Cancer», European Association of Cancer Research, XVI EACR Congress, 2000

E. Georgakopoulos*, C. Christodoulou, G. Klouvas, S. Georgakopoulou, G.Bogiatzis and D.Skarlos: « Detection of the 17-1A Antigen mRNA in Circulating Blood and the Efficacy of the Monoclonal Antibody Enderocolomab in Patients with Hormone Prostate Cancer (preliminary results)», European Association of Medical Oncology, 25th ESMO Congress, Vol.11, 2000.

S.Papandreou, S. Georgakopoulou, E. Goga, D Skarlos, G. Fountzilas and **E. Georgakopoulos**: «Molecular detection of micrometastasis and circulated cancer cells in positive node patients with breast cancer treated with E-T-CMF versus ET-CMF as adjuvant chemotherapy», Association of Biomedical Technology of Crete, November, 2000.

E. Georgakopoulos:* "Molecular Biology: Realism and Expectations", 10th Panhellenic Congress of Clinical Oncology, April 2001.

E. Georgakopoulos:* "Molecular Biology and Cancer", Lecture invited by the German Federal Minister of Health, Duesseldorf, June 2001.

Georgakopoulos E.*: «Biotechnology in Greece»**,** Biotechnology Meeting, Mykonos, July‘01.

E. Georgakopoulos:* "The contribution of molecular techniques to the determination of prognosis", HAPSc, September 2002

E. Georgakopoulos:* **"**The contribution of translational research to the establishment of new prognostic and predictive factors in breast cancer", HECOG, October 2002.

K. Vlachtsis*, C. Karanikiotes, **E. Georgakopoulos**, S. Georgakopoulou, S. Papandreou, J. Daniilidis, G. Fountzilas: «HPV and EBV infection and their relation to apoptosis and angiogenesis related proteins in operable laryngeal carcinomas», ESMO, Poster symposiumLung and head and neck cancers 1: b) Prognostic factors and biological therapies Sunday, 20 October 2002

S. Papandreou, S. Georgakopoulou, C. Karanikiotis, G. Fountzilas and **E. Georgakopoulos:*** "Detection of mRNA CK-19 and Ep-Cam antigen and micrometastatic cancer cells in patients with resectable breast cancer with positive lymph nodes receiving chemotherapy E-T-CMF vs ET-CMF" 10th Postgraduate Seminar of Clinical Oncology, Crete, November 2002.

E. Georgakopoulos:* "Molecular diagnostics and cancer. New approach to detecting residual disease. A new PCR product detection system", Panhellenic Congress of Clinical Chemistry, Athens, November 2002.

C. Karanikiotis*, K. Vlahtsis, S. Georgakopoulou, S. Papandreou, S. Gerou, and **E.**

Georgakopoulos: "Detection of the genome of the EPSTEIN – BARR virus in the peripheral blood of healthy people and its correlation with serum antibody levels" 12th Armed Forces Congress, Thessaloniki, November 2002.

***:** Presented as a lecture

Publications

Georgakopoulos E., McMenamin M. and Skouteris G. G. (1995): "Phospholipase A2 is activated by tumor necrosis factor –α in primary hepatocytes stimulated by a deleted form of hepatocyte growth factor". Biochemical and Biophysical Research Communication, **217**, 1263-1270.

Skouteris G. G. and **Georgakopoulos E**. (1996): «Hepatocyte growth factor induced proliferation of primary hepatocytes is mediated by activation of phosphatidylinositol 3-kinase». Biochemical and Biophysical Research Communication, **218**, 229-233.

Blume A., **Georgakopoulos E.**, Lebrun C., Culman J., Möllenhoff E., Herdegen T. and Unger T. (1996): **«**Arginine-vasopressin as target of angiotensin II in the brain in vitro**».** Regulatory Peptides, Volume 64, 1-3, 14.

Herdegen T., Blume A., Buschman T., **Georgakopoulos E.**, Winier C., Schmid W., Hsiem F., Zimmerman M and Gass P. (1997): «Expression of activating transcription factor-2, serum response factor and cAMP/Ca response element binding protein in the adult rat brain following generalized seizures, nerve fibre lesion and ultraviolet irradiation». Neuroscience, **81**, 190-212.

Karanikiotes C., Skiadas I., Karina M., Georgakopoulou S., **Georgakopoulos E.** and Fountzilas G (2005): «Novel chromatographic molecular method for the detection of the

membrane cancer antigen Ep-CAM (17-1A) in peripheral blood and bone marrow of patients with metastatic colorectal cancer», Anticancer Research, Jan-Feb; **25(1A)**: 319-23.

Papadopoulou E., DavilasE., Sotiriou V., **Georgakopoulos E**, Georgakopoulou S., Koliopanos K, Aggelakis F., Dardoufas K., Agnanti JN., Karydas I, Nasioulas G. (2006): «Cell-free DNA and RNA in Plasma as a New Molecular Marker for Prostate and Breast Cancer», Annals of the New York Academy of Sciences, **1075**, 2423-2435.

Georgakopoulos E. and Kakaflikas I (2006).: «Specific antioxidant rejuvenating biomolecular therapy against the ataxia Friedreich: A case report», Medical Express, **145**, 42-46.

Georgakopoulos E. (2007).: «Specific antioxidant rejuvenating biomolecular therapy against brachial amyotropfyc diplegia: A case report», Medical Express, **150**, 38-42.

Georgakopoulos E., Pouiou A. and Gianadakis E. (2007).: «Specific antioxidant rejuvenating biomolecular therapy against spinocerebellar atrophy: A case report», Medical Express, **152**, 38-44.